Amendments to the Claims

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (previously presented) A wound healing composition comprising living human dermal fibroblast cells suspended within a single-layered sterile, non-pyrogenic, solid or semi-solid, support matrix, said support matrix comprising a protein concentration of 3 to 12 $mg.ml^{-1}$ and a cell density of said human dermal fibroblasts of 450 to 2500 cells per mm^2, said composition having been incubated for 16 to 24 h at about 37°C.

Claims 2-3 (cancelled)

4. (previously presented) The wound healing composition of claim 1, having been stored after incubation for up to about 40 days at a temperature of 2°C to 8°C.

Claims 5-7 (cancelled)

8. (previously presented) The wound healing composition of claim 1, in which the composition substantially excludes keratinocytes.

9. (previously presented) The wound healing composition of claim 1, in which the cells are actively synthetic or able to become actively synthetic rapidly.

10. (previously presented) The wound healing composition of claim 1, in which the cells are not proliferating or not senescent.

Claims 11-12 (cancelled)

13. (previously presented) The wound healing composition of claim 1, in which the matrix comprises fibrin.

14. (previously presented) The wound healing composition of claim 13, in which the support matrix has a fibrin concentration in the range of 3 to 12 $mg.ml^{-1}$.

15. (previously presented) The wound healing composition of claim 13, in which the fibrin matrix has been formed by thrombin-mediated polymerisation of fibrinogen.

16. (cancelled)

17. (previously presented) The wound healing composition of claim 1, further comprising a protease inhibitor.

18. (previously presented) The wound healing composition of claim 1, in which the composition has been incubated in a protein-rich environment.

19. (previously presented) The wound healing composition of claim 1, in which the composition has a thickness of approximately 8 mm or less.

Claims 20-22 (cancelled)

23. (previously presented) The wound healing composition of claim 1, in which the composition is packaged in a container suitable for transporting the composition, storing the composition, or topically applying the composition to a skin surface.

24. (previously presented) The wound healing composition of claim 23, in which the container comprises a flexible pouch comprising two sheets of impermeable flexible material peripherally sealed to contain the composition, the pouch comprising a first internal surface to which the composition is adherent at a level of adhesion more than between the composition and a second internal surface of the pouch but less than that between the composition and the skin surface, such that in use the pouch may be opened by parting the sheets and the composition conveniently manipulated and directly applied to the skin surface without further requirement for the composition to be directly touched prior to application.

25. (previously presented) The wound healing composition of claim 23, in which the container is sterile.

26. (previously presented) The wound healing composition of claim 1, for use as a medicament.

27. (previously presented) The wound healing composition of claim 1, for use as a medicament in the treatment of a skin lesion.

28. (previously presented) The wound healing composition of claim 26, wherein said medicament is used for topical application to a skin lesion.

Claims 29-38 (cancelled)

39. (previously presented) The wound healing composition of claim 4, in which the composition has been stored after incubation for up to about 19 days.

40. (previously presented) The wound healing composition of claim 39, in which the composition has been stored after incubation for about 7 to 14 days.

41. (previously presented) The wound healing composition of claim 4, in which the composition has been stored after incubation at a temperature of 3°C to 5°C.

42. (previously presented) The wound healing composition of claim 41, in which the composition has been stored after incubation at a temperature of about 4°C.

43. (cancelled)

44. (previously presented) The wound healing composition of claim 6, in which said human dermal fibroblasts comprise between about 90% to 100% of the cells of said composition.

45. (cancelled)

46. (previously presented) The wound healing composition of claim 1, in which the cells are suspended substantially uniformly within the matrix.

47. (cancelled)

48. (previously presented) The wound healing composition of claim 14, in which the support matrix has a fibrin concentration in the range of 3 to 5 $mg.ml^{-1}$ or 7 to 12 $mg.ml^{-1}$.

49. (previously presented) The wound healing composition of claim 17, wherein said protease inhibitor is aprotinin or tranexamic acid.

50. (previously presented) The wound healing composition of claim 19, in which the composition has a thickness of approximately 5 mm or less.

51. (previously presented) The wound healing composition of claim 28, wherein said skin lesion is a venous ulcer, diabetic ulcer, pressure sore, burn or iatrogenic grating wound.

Claims 52-62 (cancelled)

63. (new) The wound healing composition of claim 1, wherein the composition consists of living human dermal fibroblast cells suspended within a single-layered sterile, non-pyrogenic, solid or semi-solid, support matrix.

64. (new) The wound healing composition of claim 1, wherein the composition comprises no additional cellular layers.

65. (new) The wound healing composition of claim 1, wherein the composition comprises stacked layers comprising substantially uniform single layers.